May 11, 2022 10:07 AM EDT
Bioregnum
R&D

The col­lapse of SKY­SCRAPER-01 is cast­ing a pall over all the TIG­ITs. Are we in for an­oth­er I/O fi­as­co?

The first time Roche re­port­ed a fail­ure for its sweep­ing Phase III pro­gram for the TIG­IT con­tender tiragolum­ab a cou­ple of months ago, quite a …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

Gilead will close Philadel­phia, Seat­tle of­fices as part of job re­duc­tions

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times